Market Expansion Opportunity Recent EC approval for Novartis' Kisqali in a broad population of early breast cancer patients opens up new market segments and potential sales growth.
Strategic Sales Boost Novartis raising sales outlook and acquiring Kate Therapeutics indicates a strategic focus on expanding product portfolio, which can lead to increased sales opportunities in the future.
Long-Term Revenue Growth Novartis anticipates a 6% annual growth in sales through 2028, signaling a stable revenue stream and providing a reliable target for sales forecasting and planning.
Market Positioning Advantage Novartis showcasing new trial results at major events like ASH and SABCS highlights the company's innovative capabilities, enhancing its brand reputation and potentially attracting more customers.
Competitive Market Edge Despite similar companies like Roche and AstraZeneca in the market, Novartis' continuous focus on new drug launches and revenue growth projections positions it competitively, offering sales professionals leverage in negotiations.
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1BNovartis uses 8 technology products and services including Medallia, Commvault, FactSet, and more. Explore Novartis's tech stack below.
| Novartis Email Formats | Percentage |
| First.Last@novartis.com | 90% |
| F.Last@novartis.com | 6% |
| FLast@novartis.com | 3% |
| First.L@novartis.com | 1% |
| First.Last@group.novartis.com | 96% |
| Last@group.novartis.com | 3% |
| Last.First@group.novartis.com | 1% |
| First.Last@pharma.novartis.com | 90% |
| Last.First@pharma.novartis.com | 1% |
| First.MiddleLast@pharma.novartis.com | 1% |
| F_Last@pharma.novartis.com | 1% |
| LastFirst@pharma.novartis.com | 1% |
| FLast@pharma.novartis.com | 1% |
| FirLast@pharma.novartis.com | 1% |
| First.Middle@pharma.novartis.com | 1% |
| Last_First@pharma.novartis.com | 1% |
| First_Last@pharma.novartis.com | 1% |
| FirstMiddle.Last@pharma.novartis.com | 1% |
Pharmaceutical ManufacturingBaselstadt, Switzerland10001+ Employees
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Company Overview
Media & News
Funding & FinancialsNovartis has raised a total of $2.5B of funding over 2 rounds. Their latest funding round was raised on Jun 19, 2024 in the amount of $2.5B.
Novartis's revenue is in the range of $1B
Funding & FinancialsNovartis has raised a total of $2.5B of funding over 2 rounds. Their latest funding round was raised on Jun 19, 2024 in the amount of $2.5B.
Novartis's revenue is in the range of $1B
1-888-653-2347 
support@leadiq.com